Korea Investment CORP Invests $25.93 Million in Kenvue Inc. $KVUE

Korea Investment CORP purchased a new position in shares of Kenvue Inc. (NYSE:KVUE) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,356,959 shares of the company’s stock, valued at approximately $25,931,000. Korea Investment CORP owned about 0.07% of Kenvue as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. EP Wealth Advisors LLC purchased a new stake in Kenvue during the 2nd quarter worth approximately $272,000. Heartland Bank & Trust Co acquired a new position in shares of Kenvue during the second quarter valued at approximately $231,000. Ieq Capital LLC acquired a new position in shares of Kenvue during the second quarter valued at approximately $3,549,000. Callan Family Office LLC purchased a new position in shares of Kenvue in the second quarter valued at approximately $835,000. Finally, Keating Financial Advisory Services Inc. purchased a new position in shares of Kenvue in the second quarter valued at approximately $38,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on KVUE shares. Wall Street Zen lowered Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings raised Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. Zacks Research lowered Kenvue from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Barclays lifted their target price on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 21st. Finally, UBS Group dropped their target price on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Tuesday, August 11th. Three investment analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company. Based on data from MarketBeat, Kenvue presently has a consensus rating of “Hold” and a consensus target price of $19.27.

Kenvue Trading Up 0.1%

Shares of Kenvue stock opened at $19.08 on Monday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.01 and a quick ratio of 0.71. The stock’s 50 day simple moving average is $19.05 and its 200-day simple moving average is $18.20. The stock has a market cap of $36.65 billion, a P/E ratio of 21.93, a P/E/G ratio of 1.36 and a beta of 0.47. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $21.78.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.31 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.01). Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The company had revenue of $3.96 billion during the quarter, compared to analyst estimates of $3.97 billion. During the same period in the prior year, the business posted $0.29 EPS. Kenvue’s revenue for the quarter was up 3.0% compared to the same quarter last year. Analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, August 26th. Shareholders of record on Wednesday, August 12th will be issued a $0.21 dividend. This represents a $0.84 annualized dividend and a yield of 4.4%. The ex-dividend date is Wednesday, August 12th. This is an increase from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s dividend payout ratio (DPR) is currently 96.55%.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.